Article Details
Retrieved on: 2018-02-13 20:45:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>The idea <b>DNAnexus</b> has is that the clinical trials that have a target biomarker identified in early stage will be able to save cost and significantly increase success rate down the development road. And the ready availability of NGS provides an easier access to genomics data, enabling researchers to select ...</div>
Article found on:
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here